BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Daewoong Pharma, Hanall Biopharma invest $1M for new cancer cell therapies

August 20, 2021 | News

Accelerating development of Alloplex's lead program, SUPLEXA Therapeutic Cells, the next generation tumor agnostic cellular therapy for treating solid and liquid tumors.



Daewoong Pharmaceutical and Hanall Biopharma of South Korea are expanding their global open collaboration initiative by investing in Alloplex Biotherapeutics, an emerging Boston-based biotechnology company.

Daewoong Pharmaceutical and Hanall Biopharma have announced their investment in Alloplex Biotherapeutics by purchasing to support a potential long-term collaboration for developing new cancer cell therapies. Daewoong Pharmaceutical and Hanall Biopharma aim to collaborate with Alloplex to develop global networks and communication with experts in this domain.

This investment will allow Alloplex to advance its first-generation SUPLEXA therapeutic cell program into the clinic by the first half of 2022. SUPLEXA Therapeutic Cells are a differentiated and non-engineered autologous therapy made from activated and reprogrammed peripheral blood mononuclear cells (PBMC) - derived from patient whole blood. SUPLEXA cells are generated in rapidly and in abundance through a robust ex vivo manufacturing procedure during which they acquire the capacity to kill all tumor cells tested without affecting normal cells. SUPLEXA cells are comprised of a heterogenous mixture of cells of both innate and adaptive phenotypes known for their anti-tumor activity, including NK, NKT, CD8+ CTL and gd T cells.

As such SUPLEXA cells employ a multi-modal anti-tumor strategy comprised entirely of normal activated immune cells with a capacity to kill all tumor cells tested. It is postulated that by using the patient's own cells rather than external substances that this therapy may have a very benign safety profile while maximizing anti-cancer effects.